On September 9, 2026 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel New York in New York City on Wednesday, September 23, 2026, beginning at 10:00 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To register to attend the event in person or virtually, please RSVP by clicking here.
"We look forward to gathering with investors and scientific leaders to showcase key progress across our IMNN-001 clinical program," said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. "With our Phase 3 OVATION 3 trial advancing and insightful data emerging from our Phase 2 MRD study, this event highlights our commitment to redefining treatment paradigms for women facing advanced ovarian cancer. A highlight of the event will be a conversation with an OVATION 1 clinical trial participant who received IMNN-001 in the study."
The event will feature a conversation with an OVATION 1 clinical trial participant offering a firsthand perspective on her experience in the study and in the years following the trial. Presentations will include leading experts in ovarian cancer and principal investigators involved in the Company’s Phase 3 OVATION 3 clinical trial and the Phase 2 minimal residual disease (MRD) clinical trial, conducted in partnership with the Break Through Cancer Foundation.
Members of IMUNON’s management team will join these experts to deliver updates on new IMNN-001 data and discuss the potential role of IMNN-001 in transforming the treatment landscape for women with advanced ovarian cancer. A live Q&A session and networking opportunities will follow the formal presentations.
Featured Presentations and Speakers:
Redefining Frontline Care — Unlocking the Potential of a First-in-Class IL-12 Immunotherapy in Ovarian Cancer
Presenter: Stacy R. Lindborg, Ph.D., President and Chief Executive Officer, IMUNON, Inc.
Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas Delivery of IMNN-001
Presenter: Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, IMUNON, Inc.
Unveiling Translational Insights — MRD Clearance, Microenvironment Remodeling, and Combination Strategies
Presenter: Amir Jazaeri, M.D., Vice Chair for Clinical Research, Director, Gynecologic Cancer Immunotherapy Program, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center
Advancing Frontline Efficacy — Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3
Presenter: Premal H. Thaker, M.D., David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Chief of Gynecologic Oncology, Director of Gynecologic Oncology Clinical Research, Professor in Gynecologic Oncology, Washington University School of Medicine
Beyond the Data: Clinical Experience with IMNN-001 — A Conversation with an OVATION 1 Study Participant
Presenter: OVATION 1 clinical trial participant, with William Bradley, M.D., Professor and Vice Chair for Clinical Research, Division of Gynecologic Oncology, Medical College of Wisconsin
Building the Future — Strategic Milestones, Catalysts, and the Investment Horizon
Presenter: Stacy R. Lindborg, Ph.D., President and Chief Executive Officer, IMUNON, Inc.
About IMNN-001 Immunotherapy
Designed using IMUNON’s proprietary TheraPlas platform technology, IMNN-001 is an IL-12 DNA plasmid encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m² administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.
(Press release, IMUNON, SEP 9, 2026, View Source [SID1234670679])